222 related articles for article (PubMed ID: 20056651)
21. Randomized phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by Paclitaxel for early breast cancer.
Martín M; Rodríguez-Lescure A; Ruiz A; Alba E; Calvo L; Ruiz-Borrego M; Munárriz B; Rodríguez CA; Crespo C; de Alava E; López García-Asenjo JA; Guitián MD; Almenar S; González-Palacios JF; Vera F; Palacios J; Ramos M; Gracia Marco JM; Lluch A; Alvarez I; Seguí MA; Mayordomo JI; Antón A; Baena JM; Plazaola A; Modolell A; Pelegrí A; Mel JR; Aranda E; Adrover E; Alvarez JV; García Puche JL; Sánchez-Rovira P; Gonzalez S; López-Vega JM;
J Natl Cancer Inst; 2008 Jun; 100(11):805-14. PubMed ID: 18505968
[TBL] [Abstract][Full Text] [Related]
22. Expression of E-cadherin, beta-catenin, cathepsin D, gelatinases and their inhibitors in invasive ductal breast carcinomas.
Zhang YG; DU J; Tian XX; Zhong YF; Fang WG
Chin Med J (Engl); 2007 Sep; 120(18):1597-605. PubMed ID: 17908479
[TBL] [Abstract][Full Text] [Related]
23. The expression pattern of MUC1 (EMA) is related to tumour characteristics and clinical outcome of invasive ductal breast carcinoma.
van der Vegt B; de Roos MA; Peterse JL; Patriarca C; Hilkens J; de Bock GH; Wesseling J
Histopathology; 2007 Sep; 51(3):322-35. PubMed ID: 17645748
[TBL] [Abstract][Full Text] [Related]
24. Epidermal growth factor receptor (EGFR) and the estrogen receptor modulator amplified in breast cancer (AIB1) for predicting clinical outcome after adjuvant tamoxifen in breast cancer.
Dihge L; Bendahl PO; Grabau D; Isola J; Lövgren K; Rydén L; Fernö M
Breast Cancer Res Treat; 2008 May; 109(2):255-62. PubMed ID: 17636398
[TBL] [Abstract][Full Text] [Related]
25. Clinicopathologic analysis of breast cancers with PIK3CA mutations in Japanese women.
Maruyama N; Miyoshi Y; Taguchi T; Tamaki Y; Monden M; Noguchi S
Clin Cancer Res; 2007 Jan; 13(2 Pt 1):408-14. PubMed ID: 17202311
[TBL] [Abstract][Full Text] [Related]
26. Estrogen receptor co-activator (AIB1) protein expression by automated quantitative analysis (AQUA) in a breast cancer tissue microarray and association with patient outcome.
Harigopal M; Heymann J; Ghosh S; Anagnostou V; Camp RL; Rimm DL
Breast Cancer Res Treat; 2009 May; 115(1):77-85. PubMed ID: 18521745
[TBL] [Abstract][Full Text] [Related]
27. Cytoplasmic beta-catenin accumulation is a good prognostic marker in upper and lower gastrointestinal adenocarcinomas.
Norwood MG; Bailey N; Nanji M; Gillies RS; Nicholson A; Ubhi S; Darnton JJ; Steyn RS; Womack C; Hughes A; Hemingway D; Harrison R; Waters R; Jankowski JA
Histopathology; 2010 Jul; 57(1):101-11. PubMed ID: 20572881
[TBL] [Abstract][Full Text] [Related]
28. Expression and possible prognostic role of MAGE-A4, NY-ESO-1, and HER-2 antigens in women with relapsing invasive ductal breast cancer: retrospective immunohistochemical study.
Bandić D; Juretić A; Sarcević B; Separović V; Kujundzić-Tiljak M; Hudolin T; Spagnoli GC; Cović D; Samija M
Croat Med J; 2006 Feb; 47(1):32-41. PubMed ID: 16489695
[TBL] [Abstract][Full Text] [Related]
29. beta-Catenin and p53 analyses of a breast carcinoma tissue microarray.
Chung GG; Zerkowski MP; Ocal IT; Dolled-Filhart M; Kang JY; Psyrri A; Camp RL; Rimm DL
Cancer; 2004 May; 100(10):2084-92. PubMed ID: 15139049
[TBL] [Abstract][Full Text] [Related]
30. Caveolin-1 is down-regulated and inversely correlated with HER2 and EGFR expression status in invasive ductal carcinoma of the breast.
Park SS; Kim JE; Kim YA; Kim YC; Kim SW
Histopathology; 2005 Dec; 47(6):625-30. PubMed ID: 16324201
[TBL] [Abstract][Full Text] [Related]
31. Retention of the expression of E-cadherin and catenins is associated with shorter survival in grade III ductal carcinoma of the breast.
Gillett CE; Miles DW; Ryder K; Skilton D; Liebman RD; Springall RJ; Barnes DM; Hanby AM
J Pathol; 2001 Apr; 193(4):433-41. PubMed ID: 11276001
[TBL] [Abstract][Full Text] [Related]
32. Cytoplasmic HuR expression is a prognostic factor in invasive ductal breast carcinoma.
Heinonen M; Bono P; Narko K; Chang SH; Lundin J; Joensuu H; Furneaux H; Hla T; Haglund C; Ristimäki A
Cancer Res; 2005 Mar; 65(6):2157-61. PubMed ID: 15781626
[TBL] [Abstract][Full Text] [Related]
33. Alpha- and beta-adrenergic receptor (AR) protein expression is associated with poor clinical outcome in breast cancer: an immunohistochemical study.
Powe DG; Voss MJ; Habashy HO; Zänker KS; Green AR; Ellis IO; Entschladen F
Breast Cancer Res Treat; 2011 Nov; 130(2):457-63. PubMed ID: 21298476
[TBL] [Abstract][Full Text] [Related]
34. RET finger protein expression in invasive breast carcinoma: relationship between RFP and ErbB2 expression.
Tezel GG; Uner A; Yildiz I; Guler G; Takahashi M
Pathol Res Pract; 2009; 205(6):403-8. PubMed ID: 19232840
[TBL] [Abstract][Full Text] [Related]
35. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
[TBL] [Abstract][Full Text] [Related]
36. [Correlation among expression of E-cadherin, beta-catenin, and cyclin D1 in breast cancers].
Yang JF; Chen SL; Liu ZH; Zhang Y
Ai Zheng; 2004 Jul; 23(7):799-802. PubMed ID: 15248915
[TBL] [Abstract][Full Text] [Related]
37. Immunolocalization of the fodrin, E-cadherin, and beta-catenin adhesion complex in infiltrating ductal carcinoma of the breast-comparison with an in vitro model.
Sormunen RT; Leong AS; Vääräniemi JP; Fernando SS; Eskelinen SM
J Pathol; 1999 Mar; 187(4):416-23. PubMed ID: 10398100
[TBL] [Abstract][Full Text] [Related]
38. Tissue microarray analysis of beta-catenin in colorectal cancer shows nuclear phospho-beta-catenin is associated with a better prognosis.
Chung GG; Provost E; Kielhorn EP; Charette LA; Smith BL; Rimm DL
Clin Cancer Res; 2001 Dec; 7(12):4013-20. PubMed ID: 11751495
[TBL] [Abstract][Full Text] [Related]
39. Stromal CD10 expression and relationship to the E-cadherin/beta-catenin complex in breast carcinoma.
Kim HS; Kim GY; Kim YW; Park YK; Song JY; Lim SJ
Histopathology; 2010 May; 56(6):708-19. PubMed ID: 20546336
[TBL] [Abstract][Full Text] [Related]
40. PIK3CA mutations mostly begin to develop in ductal carcinoma of the breast.
Li H; Zhu R; Wang L; Zhu T; Li Q; Chen Q; Wang H; Zhu H
Exp Mol Pathol; 2010 Feb; 88(1):150-5. PubMed ID: 19818761
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
